Preferential histiotypic expression of CD44-isoforms in human lung cancer

Anja Wimmel(Philipps University of Marburg), Marcus Schuermann(Philipps University of Marburg), M. Schilli(Philipps University of Marburg), Ulrich Kaiser(University of Applied Sciences Landshut), D. Branscheid, Е А Коган(Sechenov University), A. Ramaswamy(Philipps University of Marburg), K. Havemann(Philipps University of Marburg)

Lung Cancer

March 1, 1997

10.1016/s0169-5002(96)00625-3

Cited by 23

Related Papers

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

|The Lancet|2013|1.5k

Osteosarcoma Relapse After Combined Modality Therapy: An Analysis of Unselected Patients in the Cooperative Osteosarcoma Study Group (COSS)

|Journal of Clinical Oncology|2005|654

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

|The Lancet Oncology|2015|402

Incidence and risk factors of central nervous system recurrence in aggressive lymphoma—a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)

|Annals of Oncology|2006|280

Second and Subsequent Recurrences of Osteosarcoma: Presentation, Treatment, and Outcomes of 249 Consecutive Cooperative Osteosarcoma Study Group Patients

|Journal of Clinical Oncology|2008|235